Elranatamab: Clinical Trials

22 trials of Elranatamab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 recruiting, 2 active not recruiting, 2 completed, 2 not yet recruiting. 22 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 222Recruiting 16, Active not recruiting 2, Completed 2, Not yet recruiting 2
Phase 15Recruiting 5

Follow Elranatamab: new trials by email Literature Review of Elranatamab trials Research Report on Elranatamab

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Dexamethasone, Mezigdomide, Elranatamab - Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Phase 2Not yet recruitingPETHEMA Foundation602026-11-012026-10-28
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory
Phase 2RecruitingSCRI Development Innovations, LLC462026-09-012026-09-04
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
BCMA bispecific - Amyloid Light-chain Amyloidosis
Phase 2Not yet recruitingCase Comprehensive Cancer Center642026-08-012026-08-05
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Elranatamab - Phase 2, Radiotherapy-Induced Immune Priming
Phase 2RecruitingM.D. Anderson Cancer Center342026-03-312026-09-18
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Elranatamab, Mezigdomide, Dexamethasone - Multiple Myeloma
Phase 1 / Phase 2RecruitingCelgene622025-10-072026-09-02
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
Lenalidomide, Dexamethasone, Elranatamab - Multiple Myeloma
Phase 2RecruitingUniversity of Miami1042025-09-162026-09-21
Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Letermovir - Relapsed Refractory Multiple Myeloma (RRMM)
Phase 2RecruitingSeoul National University Hospital402025-09-112025-12-03
ELISA in Relapsed/Refractory MM
elranatamab, Isatuximab SC, Isatuximab SC-OBDS - Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma
Phase 2RecruitingMassachusetts General Hospital302025-08-142026-09-16
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Phase 2RecruitingSCRI Development Innovations, LLC1002025-08-082026-06-04
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma
Phase 2Active not recruitingNantes University Hospital1762025-07-092026-11-13
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Elranatamab - Myeloma
Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute392025-05-272025-12-03
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Elranatamab - Multiple Myeloma
Phase 2RecruitingThomas Lund202025-01-292026-02-10
Elranatamab in Relapsed/Refractory Multiple Myeloma
Elranatamab - Multiple Myeloma
Phase 2RecruitingUniversity of California, San Diego332024-12-182026-02-20
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Elranatamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM)
Phase 1 / Phase 2RecruitingYOUNGIL KOH752024-11-262025-12-03
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Elranatamab - AL Amyloidosis
Phase 1 / Phase 2RecruitingDana-Farber Cancer Institute492024-11-012026-08-19
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Elranatamab, Lenalidomide, Plerixafor - Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy
Phase 2RecruitingM.D. Anderson Cancer Center402024-07-172026-08-10
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
Elranatamab - Smoldering Multiple Myeloma
Phase 2Active not recruitingEuropean Myeloma Network B.V.502024-05-142026-09-02
Elranatamab in R/R Multiple Myeloma
Elranatamab - Refractory Multiple Myeloma, Relapse Multiple Myeloma
Phase 2RecruitingMassachusetts General Hospital322024-03-082026-08-31
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
AZD0305, Elranatamab, Pomalidomide - Multiple Myeloma
Phase 1 / Phase 2RecruitingAstraZeneca2262023-12-052026-10-30
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Elranatamab - Elranatamab, Myeloma
Phase 2CompletedPfizer392021-12-212026-09-29

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Multiple Myeloma (18)  ·  Recurrence (3)  ·  Immunoglobulin Light-chain Amyloidosis (2)  ·  Neoplasms, Plasma Cell (2)  ·  Blood Protein Disorders (1)  ·  Cardiovascular Diseases (1)  ·  Hematologic Diseases (1)  ·  Hematologic Neoplasms (1)  ·  Hemorrhagic Disorders (1)  ·  Hemostatic Disorders (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoma, T-Cell, Peripheral (1)

Sponsors

M.D. Anderson Cancer Center (2)  ·  Massachusetts General Hospital (2)  ·  Pfizer (2)  ·  SCRI Development Innovations, LLC (2)  ·  AstraZeneca (1)  ·  Case Comprehensive Cancer Center (1)  ·  Celgene (1)  ·  CellCentric Ltd. (1)  ·  Dana-Farber Cancer Institute (1)  ·  European Myeloma Network B.V. (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Nantes University Hospital (1)  ·  PETHEMA Foundation (1)  ·  Seoul National University Hospital (1)  ·  Thomas Lund (1)

Countries

United States (15)  ·  France (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  China (3)  ·  Canada (2)  ·  Germany (2)  ·  Japan (2)  ·  Norway (2)  ·  South Korea (2)  ·  Australia (1)  ·  Brazil (1)  ·  Denmark (1)  ·  Greece (1)  ·  Italy (1)

Top investigators

Noopur Raje, MD (2)  ·  Ah-Reum Jeong (1)  ·  Albert Oriol, PhD (1)  ·  Carl O Landgren, MD (1)  ·  Christine Ye, MD (1)  ·  Enrique Ocio, PhD (1)  ·  Giada Bianchi (1)  ·  Hans Lee, MD (1)  ·  Henning Schade, MD (1)  ·  Melissa Alsina, MD (1)  ·  Qaiser Bashir, MD (1)  ·  Sandra Mazzoni, DO (1)  ·  Thomas Lund, MD (1)

Results publications

PMID 40000533, PMID 40826257, PMID 42287565

NIH funding

2023 (1), 2025 (1)